Soticlestat
Small moleculeexperimental
Clinical trial activity
21 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
9
Phase 3
4
Phase 4
0
Earliest trial started Jul 1, 2014 (NCT02201056)
Timeline
Indications
Studied for
- Chromosomes, Human, Pair 15 · Phase 2
- Complex Regional Pain Syndromes · Phase 2
- Epilepsies, Myoclonic · Phase 2
- Epilepsy · Phase 2
- Genetic Diseases, Inborn · Phase 2
- Growth and Development · Phase 2
- Guillain-Barre Syndrome · Phase 3
- Healthy Volunteers · Phase 1
- Lennox Gastaut Syndrome · Phase 3
- Liver Diseases · Phase 1
Mechanism of action
- Cholesterol 24-hydroxylaseINHIBITOR
Cholesterol 24-hydroxylase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1cccnc1-c1ccncc1)N1CCC(O)(Cc2ccccc2)CC1- Mol. weight
- 373.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298172 ↗
Also known as
- tak-935
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06422377 | Phase 3 | Apr 25, 2024 | Takeda |
| NCT05602818 | Phase 1 | Nov 15, 2022 | Takeda |
| NCT05309902 | Phase 1 | Oct 11, 2022 | Takeda |
| NCT05284760 | Phase 1 | Mar 11, 2022 | Takeda |
| NCT05163314 | Phase 3 | Jan 31, 2022 | Takeda |
| NCT05098041 | Phase 1 | Nov 22, 2021 | Takeda |
| NCT04940624 | Phase 3 | Oct 28, 2021 | Takeda |
| NCT05098054 | Phase 1 | Oct 28, 2021 | Takeda |
| NCT05064449 | Phase 1 | Oct 14, 2021 | Takeda |
| NCT04938427 | Phase 3 | Sep 29, 2021 | Takeda |
| NCT04461483 | Phase 1 | Aug 13, 2020 | Takeda |
| NCT04992442 | Phase 1 | Jul 9, 2020 | Takeda |
| NCT03990649 | Phase 2 | Jul 26, 2019 | Millennium Pharmaceuticals, Takeda |
| NCT03694275 | Phase 2 | Sep 10, 2018 | Ovid Therapeutics Inc., Takeda |
| NCT03650452 | Phase 2 | Aug 8, 2018 | Ovid Therapeutics Inc., Takeda |
| NCT03635073 | Phase 2 | Jul 19, 2018 | Ovid Therapeutics Inc., Takeda |
| NCT03166215 | Phase 2 | Jun 13, 2017 | Ovid Therapeutics Inc., Takeda |
| NCT02906813 | Phase 1 | Oct 1, 2016 | Takeda |
| NCT02539134 | Phase 1 | Sep 1, 2015 | Takeda |
| NCT02497235 | Phase 1 | Jul 1, 2015 | Takeda |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 21 | 20 | 3 | 2014 |
| Ovid Therapeutics Inc. | For profit | 4 | 0 | 1 | 2017 |
| Millennium Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1